Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
Ford
Patricia A
PA
Stem Cell Transplant Program and Center for Bloodless Medicine and Surgery, Pennsylvania Hospital, Philadelphia, Pennsylvania 19106, USA. PAFord1@juno.com
Mastoris
Jason
J
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004920:Erythropoiesis; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D000090463:Iron Deficiencies; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D007501:Iron